





Figure S1. Phosphorylation of ALG-1 serine 642 impairs the function of ALG-1.

(A) Representative CID fragment spectrum of a *C. elegans* ALG-1 peptide from a LC-UHR-QTOF run. Monophosphorylated ALG-1 peptide IpSNDAGMPIVGNPCFCK. Monoisotopic mass: 1917.78 Da, Mascot ion score: 21, Expectation value: 0.0089, Δ mass: -0.01 Da. Phosphosite localization at position 642 according to Mascot.

(**B**) alg-1(0) mutant animals carrying extrachromosomal transgene arrays of wild-type ALG-1 (WT), alg-1(S642A) or alg-1(S642E) were used to evaluate the ability of the transgenes to rescue the alae formation defects of alg-1(0) mutant animals. Young adult animals were monitored with Nomarski DIC microscopy to determine the structure of alae (complete or defective). The graph reports the fraction of animals with alae defect for each genotype. *P*-values were measured with a two-tailed Fisher's exact test, *** indicates p<0.001 and **** indicates p<0.0001. The sample size (n=) used for quantification is indicated.

(C) The same genotypes expressing transgenes of alg-l as in (B) were fed with bacteria that produce a control double-stranded RNA or double-stranded RNA containing alg-2 sequence to trigger RNAi. The fraction of lethal or sterile adult animal for each transgenic strain is reported. *P*-values were measured with a two-tailed Fisher's exact test, *** indicates p<0.001 and **** indicates p<0.0001. The sample size (n=) used for quantification is indicated.

(**D**) Representative western blot of ALG-1 in wild type animals (WT), CRISPR-Cas9 edited non-phosphorylatable alg-1(S642A) and phospho-mimicking alg-1(S642E) mutants treated with proteasome inhibitor MG132 or only the vehicle (DMSO). Beta-Actin was used as a loading control. The ratio indicates the fold change compared to wild type ALG-1 (WT) treated with DMSO and normalized on Actin levels. Three replicates (n=3) of this experiment were used to calculate *P*-values with a Student's *t*-test and we report no significant difference in ALG-1 levels in worms treated with MG132 compared to only vehicle (DMSO). ALG-1 S642E levels were significantly lower than ALG-1 WT in both conditions (DMSO and DMSO+MG132) with an average fold change of 0.7 and *p*-values of 0.04 and 0.006 respectively.



Heatmap WT, alg-1(S642A) and alg-1(S642E)

Figure S2. Heatmap of miRNA expression during development.

Pairwise correlation matrix heatmap of the log2 transformed values of miRNA expression (Pearson's correlation, shown in the legend on right) obtained by small-RNA sequencing in wild-type (WT), alg-1(S642A) and alg-1(S642E) animals grown from 18h to 30h at 25°C. At each timepoint, 1500 worms were plated for each sample. Each sample was divided by the total number of reads and multiplied by the average library size. Log2 expression levels were calculated after adding a pseudocount of 8.



Figure S3. Principal Component Analysis.

Principal Component Analysis (PCA) based on miRNA expression of samples wild-type (WT), alg-1(S642A) and alg-1(S642E) grown from 18 h to 30 h at 25°C (n=1500, each timepoint per sample). Samples with similar miRNA expression profiles are clustered together. The x and y axes indicate the percentage of explained variance of the first and second principal components, respectively.





**

В

Fold change of miRNAexpression

Α



Figure S4

Figure S4. miR-35-42 and miR-51-56 miRNA families quantification in embryo and comparative guide and passenger strand expression in adults.

(A) RT-qPCR quantification of miR-35-42 and miR-51-56 miRNA family in embryos. Embryos were harvested from synchronised adult populations by alkaline hypochlorite solution treatment and incubated at room temperature for 4 hours in M9 solution with rotation before RNA extraction. The levels of the guide strands of miR-miR-35-42 miRNAs (**Top**) and miR-51-56 miRNAs (**Bottom**) in *alg-1(S642A)* and *alg-1(S642E)* embryos were measured by RT-pPCR and normalized to the levels measured in wild type embryos. Small nucleolar RNA sn2841 was used as an internal control gene. The error bars represent the 95% confidence interval from three biological replicates and the *p*-values were calculated using a two-tailed Student's *t*-test; *: p<0.05 and **: p<0.01.

(B) Fold change of normalized miRNA sequencing reads per million, expressed in \log_2 , for both the guide (miRNA) and passenger strands (miR*) miRNAs in *alg-1(S642E)* mutants compared to wild type adult animals. The normalized reads per million were averaged over three biological replicates and miRNAs for which an increase in passenger strand was measured in adult animals are shown.









Figure S5. RT-qPCR of miRNAs associated to ALG-1 and DCR-1 Co-immunoprecipitation.

(A) ALG-1 immunoprecipitation (IP) from adult animal populations expressing either wild type alg-1 (wt), alg-1(S642A) or alg-1(S642E) were performed using a specific ALG-1 polyclonal antibody. **Top**: 90% of immunoprecipitated complexes were used to detect levels of miRNAs by quantitative RT-qPCR. Samples were spiked-in with human miR-20a miRNA before RNA purification and used as a technical control. The error bars represent the 95% confidence interval from three biological replicates, * indicates the statistical significance obtained from a Student's *t*-test *p*<0.05. **Bottom**: Representative image of a western blot of ALG-1 IP for miRNA quantification. 10% of the immunoprecipitated ALG-1 complex was used to detect ALG-1 by western blot. The input is 10% of protein extract used for immunoprecipitation. The ALG-1 levels in the IP relative to the signal of WT are shown and miRNA quantification was further normalized according to these values.

(B) ALG-1 and DCR-1 co-IP. The interaction between ALG-1 (WT, S642A and S642E) and DCR-1 was evaluated by ALG-1 IP in adult animal extracts. Two biological replicates are shown. alg-1(0) animals (right panel) were used as a control.

(C) ALG-1 and DCR-1 co-IP. The interaction between ALG-1 (WT, S642A and S642E) and DCR-1 was evaluated by DCR-1 IP in embryo extracts. One biological replicate was performed.

	۱.
F	ł

Ce ALG-1	ACFAQQQHVKENDLRMFTNQLQRI S NDAGMPIVGNPCFCKYAVGVEQVEPM	668
Ce ALG-2	ACFAQQSHVKENDLRMFTTQLQRISTDAGMPIIGTPMFCKYASGVEQVEPM	553
Hs AGO1	ACFAPQKQCREEVLKNFTDQLRKI S KDAGMPIQGQPCFCKYAQGADSVEPM	503
Hs AGO2	ACFAPQRQCTEVHLKSFTEQLRKI S RDAGMPIQGQPCFCKYAQGADSVEPM	504
Hs AGO3	ACFATQRQCREEILKGFTDQLRKI S KDAGMPIQGQPCFCKYAQGADSVEPM	505
Hs_AGO4	ACFAPQKQCREDLLKSFTDQLRKI S KDAGMPIQGQPCFCKYAQGADSVEPM	496
	**** * : * *: ** **::** ***** * * ***** * .:.****	
Ce_ALG-1	ACFAQQQHVKENDLRMFTNQLQRISNDAGMPIVGNPCFCKYAVGVEQVEPM	668
Ce_ALG-5	VCFASPEIIGEASMRSFVRNLVNVASEIGMPFLEEHRFCRYAEPDQTVKL-	562

	.***. : : * .:* *:* .::: ***:: : **:** : *:	
e_ALG-5	VCFASPEIIGEASMRSFVRNLVNVASEIGMPFLEEHRFCRYAEPDQTVKL- 5	562
e_ALG-1	ACFAQQQHVKENDLRMFTNQLQRI S NDAGMPIVGNPCFCKYAVGVEQVEPM 6	56



Figure S6. Sequence alignment, accessibility on the apo ALG-1 structure and analysis of human AGO2 serine 478 mutants.

(A) **Top:** Sequence alignment of *C. elegans* miRNA-specific and four human AGO proteins. Alignment of *C. elegans* ALG-1 and ALG-2 and human AGO1-4 using Clustal Omega. **Bottom:** Sequence alignment of *C. elegans* Argonaute ALG-1 and ALG-5 using Clustal Omega.

(B) Overall structure of ALG-1 shown as a surface model.

(C) The side chain of serine 642 is depicted as a ball and stick model. The hydroxyl oxygen of S642 is colored in red. For clarity, the N-terminal extended region and the insertion in the L2 domain unique to ALG-1 are not shown.

(**D**) miRNA quantification in cells expressing AGO2 serine 478 phosphorylation mutants. Flag/HA-tagged AGO2 WT or Flag/HA-tagged AGO2 serine 478 (the conserved serine corresponding to ALG-1 serine 642) mutated into alanine (S478A) or glutamate (S478E) were transfected in HEK 293T cells to quantify miRNA expression with Northern blotting. miRNA signals were normalized to corresponding U6 snRNA signal and compared to WT expression. **Left:** Average miRNA expression in cells transfected with AGO2 S478A and AGO2 S478E relative to AGO2 WT. Three biological replicates were used for quantification (n=3) and calculated as mean. Error bars represent the standard deviation. p-values were calculated using a two-tailed Student's *t*-test and no significant difference between wild type AGO2 and mutant AGO2 was observed. **Top right:** Western blot showing representative Flag/HA AGO2 expression with HA antibody. **Bottom right:** Representative Northern blots of miR-17, miR-19b, miR-16, miR-18a, miR-92a and U6 used for quantification.

(E) RIP experiment to analyse AGO2 mRNA target binding. HEK 293T cells were transfected with FLAG/HAtagged AGO2 WT or with FLAG/HA-tagged AGO2 mutants S478A, S478E and Y529E. AGO2 Y529E was used as a control because it disrupts miRNA binding[S1]. Flag-tagged proteins were immunoprecipitated, bound RNA was extracted, and cDNA was synthesized. Target binding of AGO2 WT and mutants was analyzed by qRT-PCR. EGFP served as a negative control. Data was analyzed with the $\Delta\Delta$ Ct method as relative enrichment over input. The values were normalized to the relative amount of immunoprecipitated AGO2 protein as determined with HA antibody by Western blotting. Analysis was performed with three biological replicates and calculated as mean. Error bars represent the standard deviation. *: p<0.05, **: p<0.01, ***: p<0.001 and ****: p<0.0001 as determined with a two-tailed Student's *t*-test.

SUPPLEMENTAL INFORMATION

Table S1. Residue accessibility of the corresponding serine 642 on the human AGO1-4 structures.

The table reports if residues corresponding to ALG-1 serine 642 on human Argonautes are solvent-exposed or buried within the structure, based on published crystal structures of the human AGO1-4. The table discriminates AGO structures that are bound to a miRNA (RISC) and AGO structures that are bound to a target RNA (Target-bound RISC). The table shows the identifier for the structure in the Protein Data Bank (PDB ID), the human Argonaute (AGO1-4), the availability of the serine on the structure (exposed or buried), the reference of the published structure and the number of molecules in the crystallographic Asymmetric Structure (ASU) (# of mol/ASU).

RISC				
PDB ID	AGO	Ser corresponding to S642	Reference	# of mol/ASU
4XKT	1	exposed	[S2]	1
4KRE	1	exposed	[S3]	1
4KRF	1	buried	[S3]	1
40LA	2	buried	[S4]	1
4F3T	2	buried	[S5]	1
4W5N	2	buried	[S6]	1
5VM9	3	buried	[S7]	2
600N	4	buried	[S8]	1

Target-bound RISC

PDB ID	AGO	Ser corresponding to S642	Reference	# of mol/ASU
4W5O	2	exposed	[S6]	1
4W5Q	2	buried	[S6]	1
4W5R	2	buried	[S6]	1
4W5T	2	buried	[S6]	1
6N4O	2	buried	[S 9]	1
6MFN	2	buried	[S10]	1
6MDZ	2	buried	[S10]	2
6MFR	2	buried	[S10]	2
6NIT	2	buried	[S10]	2
				01

Table S2. Oligonucleotides used in this study.

Site directed mutagenesis			
Name	Target:	Sequence	
	modification		
mso2792	alg-1: alg-	TCAGCGGATTgctAACGACGCTG	
	1(S642A)		
mso2793	alg-1	AGCTGGTTGGTGAACATG	
mso2794	alg-1: alg-	TCAGCGGATTgaaAACGACGCTG	
	1(S642E)		
S478A-fwd	AGO2:	CTCAGAAAGATCGCGAGAGACGCCG	
	AGO2(S478A)		
S478A-rev	AGO2:	CGGCGTCTCTCGCGATCTTTCTGAG	
	AGO2(S478A)		
S478E fwd	AGO2:	CAGCTCAGAAAGATCGAGAGAGAGACGCCGGCATG	
	AGO2(S478E)		
S478E-rev	AGO2:	CATGCCGGCGTCTCTCTCGATCTTTCTGAGCTG	
	AGO2(S478E)		
Gene Editing CRI	SPR-Cas9	1	
crRNA	Target to edit	Sequence + GUUUUAGAGCUAUGCUGUUUUG linker	
crRNA30	alg-1(S642)	UGUUCACCAACCAGCUUCAGGUUUUAGAGCUAUGCUGUUUU	
		G	
crRNA41	alg-1(Y693)	CCUGGAAAAACUCCAGUUUAGUUUUAGAGCUAUGCUGUUUU	
		G	
crRNA53	kin-2(R92)	GAGCCACCAAAGAGAUCAGGGUUUUAGAGCUAUGCUGUUUU	
		G	
SSODN (HDR	Edit	Sequence	
template)	1 1/5(424)		
ssodn32	alg-1(5042A)		
GTTCTCCTTGACATGCTG		GTTCTCCTTGACATGCTG	
	$sODN31$ $alg_{1}(S642F)$ TCAAGTACTTGAACATTGGCTCAACCTGCTCGACTCCAACA		
550DN31	uig-1(5042E)	GTACTTGCAGAAGCATGGATTTCCGACGATTGCCATACCoCG	
		TCGTTctcAATgCGCTGAAGCTGGTTGGTGAACATGCGGAGATC	
		GTTCTCCTTGACATGCTG	
ssODN56	$kin_2(R92C)$	TTGTACTCGGTATCGTCCTCCTTGATTGGTTCGGCAGAGATTCC	
33001(30	<i>kin 2(1020)</i>	GGTTCTGCATCCACCactTCTCTTTGGTGGCTCCACAATGATGTC	
		GTCATCATCAGCAGCGTCCGG	
RNAi			
cDNA target	Strand	Sequence	
kin-2	forward	GCGAATTGGGTACCCATGTACGATGCCATGTTCC	
kin-2	Reverse	erse CTGCCGCTCTAGACAGGATCTCACGAACTGGTC	
2'-O-Methyl Pull-	Down		
Target	Sequence		
miR-35	5'-Biotin-ucuucacugcuaguuuccacccggugaaccuu-3'		
luciferase (non-	5'-Biotin-caucacguacgcggaauacuucgaaauguc-3'		
specific)			
RT-qPCR			
Target	Sequence		
NFIC fwd	GACCTGTACC	TGGCCTACTTTG	
NFIC rev	CACACCTGACGTGACAAAGCTC		

F8A1 fwd	GTTTGCGTCTGGGGAGGAAT
F8A1 rev	TGGTAACGTTCAGCCAACGA
ST6GALNAC6	CATTCGTGGTTGAGCACAGG
fwd	
ST6GALNAC6	CCGCTGGCTGCAGTAGTT
rev	

Data S1. The levels of let-7 family miRNAs are altered in *alg-1* serine 642 phosphorylation mutants.

Expression patterns of passenger strands (let-7-3p, miR-48-3p, miR-84-3p and miR-241-3p) and guide strands (let-7-5p, miR-48-5p, miR-84-5p and miR-241-5p) from the small-RNA seq of WT, *alg-1(S642A)* and *alg-1(S642E)* animals grown from 18h to 30 h at 25°C are plotted over time. At each timepoint, 1500 worms were plated for each sample. Read counts were normalized to reads per million and plotted in log₂. The graph for each miRNA represents reads from one biological replicate per genotype, with measurement at multiple time points.













REFERENCES

[S1] Rüdel, S., Wang, Y., Lenobel, R., Korner, R., Hsiao, H.H., Urlaub, H., Patel, D., and Meister, G. (2011). Phosphorylation of human Argonaute proteins affects small RNA binding. Nucleic Acids Res *39*, 2330-2343. 10.1093/nar/gkq1032.

[S2] Nakanishi, K., Ascano, M., Gogakos, T., Ishibe-Murakami, S., Serganov, A.A., Briskin, D., Morozov, P., Tuschl, T., and Patel, D.J. (2013). Eukaryote-specific insertion elements control human ARGONAUTE slicer activity. Cell Rep 3, 1893-1900. 10.1016/j.celrep.2013.06.010.

[S3] Faehnle, C.R., Elkayam, E., Haase, A.D., Hannon, G.J., and Joshua-Tor, L. (2013). The making of a slicer: activation of human Argonaute-1. Cell Rep 3, 1901-1909. 10.1016/j.celrep.2013.05.033.

[S4] Schirle, N.T., and MacRae, I.J. (2012). The crystal structure of human Argonaute2. Science 336, 1037-1040. 10.1126/science.1221551.

[S5] Elkayam, E., Kuhn, C.D., Tocilj, A., Haase, A.D., Greene, E.M., Hannon, G.J., and Joshua-Tor, L. (2012). The structure of human argonaute-2 in complex with miR-20a. Cell 150, 100-110. 10.1016/j.cell.2012.05.017.

[S6] Schirle, N.T., Sheu-Gruttadauria, J., and MacRae, I.J. (2014). Structural basis for microRNA targeting. Science 346, 608-613. 10.1126/science.1258040.

[S7] Park, M.S., Phan, H.D., Busch, F., Hinckley, S.H., Brackbill, J.A., Wysocki, V.H., and Nakanishi, K. (2017). Human Argonaute3 has slicer activity. Nucleic Acids Res 45, 11867-11877. 10.1093/nar/gkx916.

[S8] Park, M.S., Araya-Secchi, R., Brackbill, J.A., Phan, H.D., Kehling, A.C., Abd El-Wahab, E.W., Dayeh, D.M., Sotomayor, M., and Nakanishi, K. (2019). Multidomain Convergence of Argonaute during RISC Assembly Correlates with the Formation of Internal Water Clusters. Mol Cell 75, 725-740 e726. 10.1016/j.molcel.2019.06.011.

[S9] Sheu-Gruttadauria, J., Xiao, Y., Gebert, L.F., and MacRae, I.J. (2019). Beyond the seed: structural basis for supplementary microRNA targeting by human Argonaute2. EMBO J 38, e101153. 10.15252/embj.2018101153.

[S10] Sheu-Gruttadauria, J., Pawlica, P., Klum, S.M., Wang, S., Yario, T.A., Schirle Oakdale, N.T., Steitz, J.A., and MacRae, I.J. (2019). Structural Basis for Target-Directed MicroRNA Degradation. Mol Cell 75, 1243-1255. 10.1016/j.molcel.2019.06.019.